Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020; 19: 133-142
Ганглионейрома как феномен дозревания нейробластомы
https://doi.org/10.24287/1726-1708-2020-19-4-133-142Аннотация
Ганглионейрома (ГН) является зрелой, дифференцированной опухолью периферической нервной системы. Большинство ГН развиваются de novo, но часть новообразований может появляться в процессе лечения низкодифференцированных или недифференцированных опухолей периферической нервной системы (нейробластома) или в результате их спонтанного созревания. В статье представлено описание 3 клинических случаев спонтанного и индуцированного созревания нейробластомы (первичной опухоли и метастатического очага) до ГН. Представленные данные подчеркивают важность гистологической верификации длительно сохраняющихся или увеличивающихся в размерах очагов у пациентов с нейробластомой группы наблюдения, что критически может повлиять на тактику их дальнейшего ведения. Родители дали согласие на использование информации, в том числе фотографий детей, в научных исследованиях и публикациях.
Список литературы
1. Johnsen J.I., Dyberg C., Wickström M. Neuroblastoma – A Neural Crest Derived Embryonal Malignancy. Front Mol Neurosci 2019; 12 (9): 1–11. DOI: 10.3389/fnmol.2019.00009
2. Cecchetto G., Mosseri V., De Bernardi B., Helardot P., Monclair T., Costa E., et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23 (33): 8483– 9. DOI: 10.1200/JCO.2005.02.4661
3. Терновая Е.С., Качанов Д.Ю., Шаманская Т.В., Щербаков А.П., Варфоломеева С.Р., Рубцова Н.А. Факторы риска по данным визуализации у пациентов с нейробластомой. Обзор литературы. Российский журнал детской гематологии и онкологии 2019; 6 (3): 31–43.
4. Shimada H., Ambros I.M., Dehner L.P., Hata, J., Joshi V.V., Roald B., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86 (2): 364–72. DOI: 10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7
5. Shimada H., Umehara S., Monobe Y., Hachitanda Y., Nakagawa A., Goto S., et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. Cancer 2001; 92 (9): 2451–61. DOI: 10.1002/1097-0142(20011101)92:9<2451::aid-cncr1595>3.0.co;2-s
6. Okamatsu C., London W.B., Naranjo A., Hogarty M.D., Gastier-Foster J. M., Look A.T., et al. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood Cancer 2009; 53 (4): 563–9. DOI: 10.1002/pbc.22106
7. De Lellis R. The adrenal glands. In: Diagnostic Surgical Pathology, 3rd ed. Edited by Sternberg S.S. Philadelphia: Lippincott Williams & Wilkins; 1999; 1 (14): 589– 623.
8. Brodeur G.M., Nakagawara A., Yamashiro D.J., Ikegaki N., Liu X.G., Azar C.G., et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. Neurooncol 1997; 31 (1–2): 49–55.
9. Thiele C.J., Li Z., McKee A.E. On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res. 2009; 15 (19): 5962–7. DOI: 10.1158/1078-0432.CCR-08-065110
10. Tanaka T., Hiyama E., Sugimoto T., Sawada T., Tanabe M., Ida N. Trk A Gene expression in neuroblastoma. The clinical significance of an immunohistochemical study. Cancer 1995; 76 (6): 1086–95. DOI: 10.1002/1097-0142(19950915)76:6<1086::aid-cncr2820760625>3.0.co;2-8
11. Строганова А.М., Карселадзе А.И. Нейробластома: морфологическая структура, молекулярно-генетические особенности и прогностические факторы. Успехи молекулярной онкологии 2016; 3 (1): 32–43. DOI: 10.17650/2313-805X.2016.3.1.32-43
12. Kaufman M.R., Rhee J.S., Fuegelman L.J., Costantino P.D. Ganglioneuroma of the Parapharyngeal Space in a Pediatric Patient. Otolaryngol Head Neck Surg 2001; 124 (6): 702–4. DOI: 10.1177/019459980112400625
13. Cushing H., Wolbach S.B. The Transformation of a Malignant Paravertebral Sympathicoblastoma into a Benign Ganglioneuroma. Am J Pathol 1927; 3 (3): 203–16.7.
14. Spinelli C., Rossi L., Barbetta A., Ugolini C., Strambi S. Incidental ganglioneuromas: a presentation of 14 surgical cases and literature review. J Endocrinol Invest 2015; 38: 547–54. DOI: 10.1007/s40618-014-0226-y
15. Caballero O., Ferris J., Verdeguer A., Esquembre C., Castel V. Visualization of a ganglioneuroma by means of scintigraphy with 131-I-MIBG. Eur J Nucl Med 1986; 12 (7): 351–2. DOI:10.1007/bf00263818
16. Allende D.S., Hansel D.E, MacLennan G.T. Ganglioneuroma of the Adrenal Gland. J Urol 2009: 182 (2): 714–5. DOI: 10.1016/j.juro.2009.05.036
17. Kara T., Oztunali C. Radiologic findings of thoracic scoliosis due to giant ganglioneuroma. Clin Imaging 2013; 37: 767–8. DOI: 10.1016/j.clinimag.2012.11.003
18. Decarolis B., Simon T., Krug В., Leuschner I., Vokuhl C., Kaatsch P., et al. Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. BMC Cancer 2016; 16: 542. DOI: 10.1186/s12885-016-2513-9
19. Miyake M., Tateishi U., Maeda T., Arai Y., Seki K., Hasegawa T., et al. A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med 2006; 20 (5): 357–60. DOI: 10.1007/bf02987247
20. Lima A.F., Moreira F.C., Menezes A., Dias L. Cervical Ganglioneuroma in Pediatric Age: A Case Report Antonio. Turk Arch Otorhinolaryngol 2018; 56 (4): 237–40. DOI: 10.5152/tao.2018.3690
21. Jung H.R., Kang K.J., Kwon J.H., Kang Y.N. Adrenal ganglioneuroma with hepatic metastasis. J Korean Surg Soc 2011; 80 (4): 297–300. DOI: 10.4174/jkss.2011.80.4.297
22. Garvin J.H., Lack E.E., Berenberg W., Frantz C.N. Ganglioneuroma presenting with differentiated skeletal metastases. Report of a case. Cancer 1984; 54 (2): 357–60. DOI: 10.1002/1097-0142(19840715)54:2<357::aid-cncr2820540230>3.0.co;2-4
23. Adas M., Koc B., Adas G., Ozulker F., Aydin T. Ganglioneuroma presenting as an adrenal incidentaloma: a case report. J Med Case Rep 2014; 8: 131. DOI: 10.1186/1752-1947-8-131
24. Shulkin B.L, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39 (4): 679–88.
25. Vik T.A, Pfluger T., Kadota R., Castel V., Tulchinsky M., Farto J.C. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009; 52 (7): 784–90. DOI: 10.1002/pbc.21932
26. Sharp S.E, Gelfand M.J, Shulkin B.L. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med 2011; 41 (5): 345–53. DOI: 10.1053/j.semnuclmed.2011.05.001
27. Biasotti S., Garaventa A., Villavecchia G., Cabria M., Nantron M., De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000; 35 (2): 153– 5. DOI: 10.1002/1096-911x(200008)35:2<153::aid-mpo18>3.0.co;2-7
28. Solanki K.K., Bomanji J., Moyes J., Mather S.J., Trainer P.J, Britton K.E. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13 (7): 513–21. DOI: 10.1097/00006231-199207000-00006
29. Sharp S.E, Trout A.T., Weiss B.D., Gelfand M.J. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics 2016; 36 (1): 258–78. DOI: 10.1148/rg.2016150099
30. Feine U., Müller-Schauenburg W., Treuner J., Klingebiel T.H. Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986. Med Pediatr Oncol 1987; 15 (4): 181–7. DOI: 10.1002/mpo.2950150408
31. Heyman S/. Evans A.E., D'Angio G.J. I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol 1988; 16 (5): 337–40. DOI: 10.1002/mpo.2950160509
32. Fendler W.P., Wenter V., Thornton H.I., Ilhan H., von Schweinitz D., Coppenrath E. Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy. PLoS One 2015; 10 (7): e0132809. DOI: 10.1371/journal.pone.0132809
33. Кайлаш A., Киреева Е.Д., Вдовина И.С., Ядгаров М.Я., Шаманская Т.В., Рощин В.Ю. Неинвазивное определение неблагоприятного гистологического варианта у детей с нейрогенными опухолями по накоплению ¹²³I-МЙБГ с использованием полуколичественной и количественной оценок. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2020; 19 (1): 68–78. DOI: 10.24287/1726-1708-2020-19-1-68-78
34. Rozmus J., Langer M., Murphy J.J, Dix D. Multiple persistent ganglioneuromas likely arising from the spontaneous maturation of metastatic neuroblastoma. J Pediatr Hematol Oncol 2012; 34 (2): 151–3. DOI: 10.1097/MPH.0b013e318221ca82
35. Sаnchez-Galаn А., Barrena S., Vilanova-Sánchez A. Martín S., Lopez-Fernandez S., García P. Ganglioneuroma: to operate or not to operate. Eur J Pediatr Surg 2014; 24 (1): 25–30. DOI: 10.1055/s-0033-1358790
36. Качанов Д.Ю., Шаманская Т.В., Коновалов Д.М., Ликарь Ю.Н., Рощин В.Ю., Муфтахова Г.М. Ганглионейрома у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2014; 13 (3): 33–41.
37. Camelo М., Aponte L., Lugo-Vicente H. Dopamine-secreting adrenal ganglioneuroma in a child: beware of intraoperative rebound hypertension. J Pediatr Surg 2012; 47 (9): Е29–32. DOI: 10.1016/j.jpedsurg.2012.04.017
38. Alexander N., Sullivan K., Shaikh F., Irwin M. Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents. Pediatr Blood Cancer 2018; 65 (5): 1–9. DOI:10.1002/pbc.26964
Pediatric Hematology/Oncology and Immunopathology. 2020; 19: 133-142
Ganglioneuroma as the phenomenon of neuroblastoma maturation
https://doi.org/10.24287/1726-1708-2020-19-4-133-142Abstract
Ganglioneuroma (GN) represents a mature, well-differentiated tumor arising from the sympathetic nervous system. Mostly developing de novo, GN can appear during the treatment course of poorly differentiated or undifferentiated tumors of the sympathetic nervous system, such as neuroblastoma, or as a result of their spontaneous maturation. In this article we report three clinical cases of spontaneous and induced maturation of neuroblastoma (primary tumor and metastatic lesion) to GN. Histological verification of long-lasting stable or progressing residual tumor mases in patients with neuroblastoma stratified to the observation group plays a pivotal role as it may significantly affect the treatment course. The patients' parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.
References
1. Johnsen J.I., Dyberg C., Wickström M. Neuroblastoma – A Neural Crest Derived Embryonal Malignancy. Front Mol Neurosci 2019; 12 (9): 1–11. DOI: 10.3389/fnmol.2019.00009
2. Cecchetto G., Mosseri V., De Bernardi B., Helardot P., Monclair T., Costa E., et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23 (33): 8483– 9. DOI: 10.1200/JCO.2005.02.4661
3. Ternovaya E.S., Kachanov D.Yu., Shamanskaya T.V., Shcherbakov A.P., Varfolomeeva S.R., Rubtsova N.A. Faktory riska po dannym vizualizatsii u patsientov s neiroblastomoi. Obzor literatury. Rossiiskii zhurnal detskoi gematologii i onkologii 2019; 6 (3): 31–43.
4. Shimada H., Ambros I.M., Dehner L.P., Hata, J., Joshi V.V., Roald B., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86 (2): 364–72. DOI: 10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7
5. Shimada H., Umehara S., Monobe Y., Hachitanda Y., Nakagawa A., Goto S., et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. Cancer 2001; 92 (9): 2451–61. DOI: 10.1002/1097-0142(20011101)92:9<2451::aid-cncr1595>3.0.co;2-s
6. Okamatsu C., London W.B., Naranjo A., Hogarty M.D., Gastier-Foster J. M., Look A.T., et al. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood Cancer 2009; 53 (4): 563–9. DOI: 10.1002/pbc.22106
7. De Lellis R. The adrenal glands. In: Diagnostic Surgical Pathology, 3rd ed. Edited by Sternberg S.S. Philadelphia: Lippincott Williams & Wilkins; 1999; 1 (14): 589– 623.
8. Brodeur G.M., Nakagawara A., Yamashiro D.J., Ikegaki N., Liu X.G., Azar C.G., et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. Neurooncol 1997; 31 (1–2): 49–55.
9. Thiele C.J., Li Z., McKee A.E. On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res. 2009; 15 (19): 5962–7. DOI: 10.1158/1078-0432.CCR-08-065110
10. Tanaka T., Hiyama E., Sugimoto T., Sawada T., Tanabe M., Ida N. Trk A Gene expression in neuroblastoma. The clinical significance of an immunohistochemical study. Cancer 1995; 76 (6): 1086–95. DOI: 10.1002/1097-0142(19950915)76:6<1086::aid-cncr2820760625>3.0.co;2-8
11. Stroganova A.M., Karseladze A.I. Neiroblastoma: morfologicheskaya struktura, molekulyarno-geneticheskie osobennosti i prognosticheskie faktory. Uspekhi molekulyarnoi onkologii 2016; 3 (1): 32–43. DOI: 10.17650/2313-805X.2016.3.1.32-43
12. Kaufman M.R., Rhee J.S., Fuegelman L.J., Costantino P.D. Ganglioneuroma of the Parapharyngeal Space in a Pediatric Patient. Otolaryngol Head Neck Surg 2001; 124 (6): 702–4. DOI: 10.1177/019459980112400625
13. Cushing H., Wolbach S.B. The Transformation of a Malignant Paravertebral Sympathicoblastoma into a Benign Ganglioneuroma. Am J Pathol 1927; 3 (3): 203–16.7.
14. Spinelli C., Rossi L., Barbetta A., Ugolini C., Strambi S. Incidental ganglioneuromas: a presentation of 14 surgical cases and literature review. J Endocrinol Invest 2015; 38: 547–54. DOI: 10.1007/s40618-014-0226-y
15. Caballero O., Ferris J., Verdeguer A., Esquembre C., Castel V. Visualization of a ganglioneuroma by means of scintigraphy with 131-I-MIBG. Eur J Nucl Med 1986; 12 (7): 351–2. DOI:10.1007/bf00263818
16. Allende D.S., Hansel D.E, MacLennan G.T. Ganglioneuroma of the Adrenal Gland. J Urol 2009: 182 (2): 714–5. DOI: 10.1016/j.juro.2009.05.036
17. Kara T., Oztunali C. Radiologic findings of thoracic scoliosis due to giant ganglioneuroma. Clin Imaging 2013; 37: 767–8. DOI: 10.1016/j.clinimag.2012.11.003
18. Decarolis B., Simon T., Krug V., Leuschner I., Vokuhl C., Kaatsch P., et al. Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. BMC Cancer 2016; 16: 542. DOI: 10.1186/s12885-016-2513-9
19. Miyake M., Tateishi U., Maeda T., Arai Y., Seki K., Hasegawa T., et al. A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med 2006; 20 (5): 357–60. DOI: 10.1007/bf02987247
20. Lima A.F., Moreira F.C., Menezes A., Dias L. Cervical Ganglioneuroma in Pediatric Age: A Case Report Antonio. Turk Arch Otorhinolaryngol 2018; 56 (4): 237–40. DOI: 10.5152/tao.2018.3690
21. Jung H.R., Kang K.J., Kwon J.H., Kang Y.N. Adrenal ganglioneuroma with hepatic metastasis. J Korean Surg Soc 2011; 80 (4): 297–300. DOI: 10.4174/jkss.2011.80.4.297
22. Garvin J.H., Lack E.E., Berenberg W., Frantz C.N. Ganglioneuroma presenting with differentiated skeletal metastases. Report of a case. Cancer 1984; 54 (2): 357–60. DOI: 10.1002/1097-0142(19840715)54:2<357::aid-cncr2820540230>3.0.co;2-4
23. Adas M., Koc B., Adas G., Ozulker F., Aydin T. Ganglioneuroma presenting as an adrenal incidentaloma: a case report. J Med Case Rep 2014; 8: 131. DOI: 10.1186/1752-1947-8-131
24. Shulkin B.L, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39 (4): 679–88.
25. Vik T.A, Pfluger T., Kadota R., Castel V., Tulchinsky M., Farto J.C. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009; 52 (7): 784–90. DOI: 10.1002/pbc.21932
26. Sharp S.E, Gelfand M.J, Shulkin B.L. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med 2011; 41 (5): 345–53. DOI: 10.1053/j.semnuclmed.2011.05.001
27. Biasotti S., Garaventa A., Villavecchia G., Cabria M., Nantron M., De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000; 35 (2): 153– 5. DOI: 10.1002/1096-911x(200008)35:2<153::aid-mpo18>3.0.co;2-7
28. Solanki K.K., Bomanji J., Moyes J., Mather S.J., Trainer P.J, Britton K.E. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13 (7): 513–21. DOI: 10.1097/00006231-199207000-00006
29. Sharp S.E, Trout A.T., Weiss B.D., Gelfand M.J. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics 2016; 36 (1): 258–78. DOI: 10.1148/rg.2016150099
30. Feine U., Müller-Schauenburg W., Treuner J., Klingebiel T.H. Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986. Med Pediatr Oncol 1987; 15 (4): 181–7. DOI: 10.1002/mpo.2950150408
31. Heyman S/. Evans A.E., D'Angio G.J. I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol 1988; 16 (5): 337–40. DOI: 10.1002/mpo.2950160509
32. Fendler W.P., Wenter V., Thornton H.I., Ilhan H., von Schweinitz D., Coppenrath E. Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy. PLoS One 2015; 10 (7): e0132809. DOI: 10.1371/journal.pone.0132809
33. Kailash A., Kireeva E.D., Vdovina I.S., Yadgarov M.Ya., Shamanskaya T.V., Roshchin V.Yu. Neinvazivnoe opredelenie neblagopriyatnogo gistologicheskogo varianta u detei s neirogennymi opukholyami po nakopleniyu ¹²³I-MIBG s ispol'zovaniem polukolichestvennoi i kolichestvennoi otsenok. Voprosy gematologii/onkologii i immunopatologii v pediatrii 2020; 19 (1): 68–78. DOI: 10.24287/1726-1708-2020-19-1-68-78
34. Rozmus J., Langer M., Murphy J.J, Dix D. Multiple persistent ganglioneuromas likely arising from the spontaneous maturation of metastatic neuroblastoma. J Pediatr Hematol Oncol 2012; 34 (2): 151–3. DOI: 10.1097/MPH.0b013e318221ca82
35. Sanchez-Galan A., Barrena S., Vilanova-Sánchez A. Martín S., Lopez-Fernandez S., García P. Ganglioneuroma: to operate or not to operate. Eur J Pediatr Surg 2014; 24 (1): 25–30. DOI: 10.1055/s-0033-1358790
36. Kachanov D.Yu., Shamanskaya T.V., Konovalov D.M., Likar' Yu.N., Roshchin V.Yu., Muftakhova G.M. Ganglioneiroma u detei. Voprosy gematologii/onkologii i immunopatologii v pediatrii 2014; 13 (3): 33–41.
37. Camelo M., Aponte L., Lugo-Vicente H. Dopamine-secreting adrenal ganglioneuroma in a child: beware of intraoperative rebound hypertension. J Pediatr Surg 2012; 47 (9): E29–32. DOI: 10.1016/j.jpedsurg.2012.04.017
38. Alexander N., Sullivan K., Shaikh F., Irwin M. Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents. Pediatr Blood Cancer 2018; 65 (5): 1–9. DOI:10.1002/pbc.26964
